美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Odyssey Therapeutics

16.42

-1.5800-8.78%

盤後：16.00-0.4200-2.56%16:52 EDT

成交量：317.04萬

成交額：5,605.44萬

市值：7.39億

市盈率：-5.22

高：20.30

開：20.00

低：15.35

收：18.00

52周最高：20.30

52周最低：15.35

股本：4,499.48萬

流通股本：1,324.00萬

量比：- -

換手率：23.95%

股息：- -

股息率：- -

每股收益(TTM):-3.1460

淨資產收益率：-85.50%

總資產收益率：-41.66%

市淨率：-1.51

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Odyssey Therapeutics

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://odysseytx.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Odyssey Therapeutics, Inc.於2021年4月在特拉華州註冊成立。Odyssey是一家臨床階段的生物製藥公司，由一個尋求改變自身免疫性和炎症性疾病患者護理標準的藥物獵手團隊和董事會領導。為了實現這一目標，該公司正在開發旨在精確針對疾病病理的藥物，最初的重點是先天免疫系統。該公司相信，他們對免疫生物學的深刻理解，加上在藥物、計算和蛋白質化學、結構生物學、遺傳學和藥理學方面的領先專業知識，使他們能夠識別和藥物驅動疾病的關鍵信號節點。

董事

名稱

職位

Gary D. Glick

Chief Executive Officer and Director and President

Carolyn Ng

Independent Director

Ian F. Smith

Independent Director

Jeffrey M. Leiden

Chair and Independent Director

Ksenija Pavletic

Independent Director

Nan Li

Independent Director

Nia Tatsis

Independent Director

Paulina Hill

Independent Director

Shelley Chu

Independent Director

Timothy P. Walbert

Independent Director

Valerie Odegard

Independent Director

股東

名稱

職位

Gary D. Glick

Chief Executive Officer and Director and President

Collin Todd

Senior Vice President, Strategy and Business Development

Jason Haas

Chief Financial Officer

Anthony Opipari

Executive Vice President, Translational Medicine and Interim Chief Medical Officer

Jolie M. Siegel

Executive Vice President and General Counsel and Secretary

Natalie Dales

Chief of Research Operations and Portfolio Strategy

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ODTX/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ODTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODTX\",,,,,undefined,":{"symbol":"ODTX","market":"US","secType":"STK","nameCN":"Odyssey Therapeutics","latestPrice":16.42,"timestamp":1778270400000,"preClose":18,"halted":0,"volume":3170409,"hourTrading":{"tag":"盘后","latestPrice":16,"preClose":16.42,"latestTime":"16:52 EDT","volume":8486,"amount":141518.951416,"timestamp":1778273548200,"change":-0.42,"changeRate":-0.025579,"amplitude":0.043788},"delay":0,"changeRate":-0.08777777777777768,"floatShares":13240000,"shares":44994769,"eps":-3.146,"marketStatus":"盤後交易","change":-1.58,"latestTime":"05-08 16:55:38 EDT","open":20,"high":20.3,"low":15.35,"amount":56054422.665318005,"amplitude":0.275,"askPrice":16.71,"askSize":500,"bidPrice":15.5,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-3.146,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1778284800000},"marketStatusCode":4,"adr":0,"listingDate":1778212800000,"exchange":"NASDAQ","adjPreClose":18,"postHourTrading":{"tag":"盘后","latestPrice":16,"preClose":16.42,"latestTime":"16:52 EDT","volume":8486,"amount":141518.951416,"timestamp":1778273548200,"change":-0.42,"changeRate":-0.025579,"amplitude":0.043788},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODTX\",,,,,undefined,":{"symbol":"ODTX","floatShares":13240000,"roa":"-41.66%","roe":"-85.50%","lyrEps":0,"shares":44994769,"dividePrice":0,"high":20.3,"amplitude":0.275,"preClose":18,"low":15.35,"week52Low":15.35,"pbRate":"-1.51","psRate":"248.26","week52High":20.3,"institutionHeld":0,"latestPrice":16.42,"committee":-0.996008,"eps":-3.146,"divideRate":0,"volume":3170409,"delay":0,"ttmEps":-3.146,"open":20,"prevYearClose":18,"prevWeekClose":18,"prevMonthClose":18,"prevQuarterClose":18,"fiveDayClose":18,"twentyDayClose":18,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ODTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ODTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ODTX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://odysseytx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.1098},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.0903},{"period":"1year","weight":0.3037},{"period":"ytd","weight":0.0728}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Odyssey Therapeutics, Inc.於2021年4月在特拉華州註冊成立。Odyssey是一家臨床階段的生物製藥公司，由一個尋求改變自身免疫性和炎症性疾病患者護理標準的藥物獵手團隊和董事會領導。為了實現這一目標，該公司正在開發旨在精確針對疾病病理的藥物，最初的重點是先天免疫系統。該公司相信，他們對免疫生物學的深刻理解，加上在藥物、計算和蛋白質化學、結構生物學、遺傳學和藥理學方面的領先專業知識，使他們能夠識別和藥物驅動疾病的關鍵信號節點。","exchange":"NASDAQ","name":"Odyssey Therapeutics","nameEN":"Odyssey Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ODTX\",market:\"US\",,,undefined,":{"directors":[{"name":"Gary D. Glick","position":"Chief Executive Officer and Director and President"},{"name":"Carolyn Ng","position":"Independent Director"},{"name":"Ian F. Smith","position":"Independent Director"},{"name":"Jeffrey M. Leiden","position":"Chair and Independent Director"},{"name":"Ksenija Pavletic","position":"Independent Director"},{"name":"Nan Li","position":"Independent Director"},{"name":"Nia Tatsis","position":"Independent Director"},{"name":"Paulina Hill","position":"Independent Director"},{"name":"Shelley Chu","position":"Independent Director"},{"name":"Timothy P. Walbert","position":"Independent Director"},{"name":"Valerie Odegard","position":"Independent Director"}],"executives":[{"name":"Gary D. Glick","position":"Chief Executive Officer and Director and President"},{"name":"Collin Todd","position":"Senior Vice President, Strategy and Business Development"},{"name":"Jason Haas","position":"Chief Financial Officer"},{"name":"Anthony Opipari","position":"Executive Vice President, Translational Medicine and Interim Chief Medical Officer"},{"name":"Jolie M. Siegel","position":"Executive Vice President and General Counsel and Secretary"},{"name":"Natalie Dales","position":"Chief of Research Operations and Portfolio Strategy"}]}}}